Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 04 03:43PM ET
0.4636
Dollar change
-0.0024
Percentage change
-0.52
%
IndexRUT P/E- EPS (ttm)-2.14 Insider Own0.80% Shs Outstand192.77M Perf Week-6.27%
Market Cap90.28M Forward P/E- EPS next Y-0.62 Insider Trans-2.48% Shs Float192.36M Perf Month-18.67%
Income-303.75M PEG- EPS next Q-0.36 Inst Own42.46% Short Float25.69% Perf Quarter-54.55%
Sales54.90M P/S1.64 EPS this Y20.29% Inst Trans-27.64% Short Ratio6.75 Perf Half Y-53.64%
Book/sh0.27 P/B1.70 EPS next Y56.14% ROA-50.27% Short Interest49.42M Perf Year-84.80%
Cash/sh0.75 P/C0.62 EPS next 5Y45.80% ROE-177.63% 52W Range0.45 - 5.53 Perf YTD-66.41%
Dividend Est.- P/FCF- EPS past 5Y28.98% ROI-122.89% 52W High-91.62% Beta0.77
Dividend TTM- Quick Ratio0.57 Sales past 5Y120.02% Gross Margin-42.00% 52W Low2.36% ATR (14)0.03
Dividend Ex-Date- Current Ratio0.68 EPS Y/Y TTM-109.14% Oper. Margin-617.66% RSI (14)38.70 Volatility5.79% 6.42%
Employees375 Debt/Eq7.37 Sales Y/Y TTM483.73% Profit Margin-553.28% Recom2.80 Target Price3.00
Option/ShortYes / Yes LT Debt/Eq3.67 EPS Q/Q37.36% Payout- Rel Volume0.43 Prev Close0.47
Sales Surprise-33.62% EPS Surprise6.07% Sales Q/Q133.69% EarningsAug 14 BMO Avg Volume7.32M Price0.46
SMA20-5.28% SMA50-11.13% SMA200-50.81% Trades Volume3,040,176 Change-0.52%
Date Action Analyst Rating Change Price Target Change
Aug-15-24Downgrade JP Morgan Overweight → Neutral
Dec-11-23Downgrade HSBC Securities Hold → Reduce
Dec-08-23Upgrade Morgan Stanley Underweight → Equal-Weight $3 → $7
Oct-17-23Initiated Cantor Fitzgerald Neutral
Sep-06-23Initiated HSBC Securities Buy $4.21
Jul-19-23Upgrade BofA Securities Neutral → Buy $6 → $10
Jun-01-23Upgrade Barclays Equal Weight → Overweight $7 → $8
Apr-28-23Initiated JP Morgan Overweight $7
Mar-07-23Initiated Robert W. Baird Outperform $10
Aug-05-22Upgrade Barclays Underweight → Equal Weight
Oct-31-24 03:48AM
Oct-11-24 09:09AM
Oct-10-24 01:22PM
Oct-04-24 04:05PM
Sep-27-24 04:40PM
04:30PM Loading…
04:30PM
Sep-24-24 12:14PM
07:00AM
Sep-13-24 05:16PM
04:41PM
Aug-28-24 09:13AM
08:00AM
Aug-23-24 04:05PM
Aug-14-24 07:00AM
Aug-12-24 08:00AM
04:05PM Loading…
Aug-02-24 04:05PM
Jul-23-24 01:54PM
Jul-03-24 04:05PM
Jun-17-24 03:27PM
Jun-02-24 10:15PM
May-29-24 07:00AM
May-17-24 03:46PM
May-16-24 09:22AM
May-14-24 11:24AM
May-10-24 03:36PM
01:34PM
May-09-24 07:00AM
May-07-24 12:40PM
May-06-24 07:05AM
07:00AM
04:43PM Loading…
Apr-26-24 04:43PM
04:05PM
Apr-16-24 02:05PM
Apr-15-24 08:15AM
Apr-13-24 04:22PM
Apr-11-24 08:30AM
08:00AM
Apr-02-24 11:33AM
Mar-29-24 05:20AM
Mar-27-24 11:37AM
10:00AM
Mar-26-24 07:01AM
Mar-25-24 04:05PM
Mar-19-24 07:44AM
Mar-18-24 06:05PM
08:00AM
Mar-13-24 07:50AM
Mar-11-24 08:00AM
Mar-05-24 06:56PM
Jan-27-24 07:28AM
05:27AM
Jan-10-24 06:55AM
Jan-08-24 08:00AM
Jan-04-24 03:32PM
Jan-03-24 07:15AM
Jan-02-24 08:00AM
Dec-26-23 08:00AM
Dec-24-23 07:39AM
Dec-23-23 07:30AM
Dec-22-23 08:45AM
Dec-20-23 02:23PM
01:54PM
Dec-19-23 09:41PM
Dec-18-23 04:01PM
Dec-15-23 11:14AM
Dec-11-23 05:43AM
Dec-10-23 12:02PM
Dec-09-23 11:31AM
Dec-08-23 01:45PM
01:01PM
12:35PM
Dec-07-23 11:30AM
08:45AM
Dec-01-23 07:41AM
Nov-29-23 02:28PM
Nov-26-23 04:44PM
Nov-24-23 07:00AM
Nov-08-23 03:39PM
Nov-07-23 05:18PM
08:00AM
07:46AM
07:27AM
07:00AM
Nov-04-23 08:45AM
Nov-02-23 09:37AM
Oct-30-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 09:47AM
Sep-29-23 09:00AM
Sep-20-23 07:21AM
Sep-12-23 07:00AM
05:14AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
07:18AM
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klima Thomas JSee RemarksSep 30 '24Sale0.531,006529170,000Oct 02 04:06 PM
Obenshain AndrewPresident and CEOSep 30 '24Sale0.5334,78018,270375,218Oct 02 04:06 PM
Obenshain AndrewOfficerSep 30 '24Proposed Sale0.5234,78018,086Oct 01 03:10 PM
Klima Thomas JOfficerSep 30 '24Proposed Sale0.521,006523Oct 01 01:33 PM
Klima Thomas JSee RemarksJun 03 '24Sale0.973,8343,726121,006Jun 04 04:22 PM
Colvin Richard AChief Medical OfficerMar 01 '24Sale1.536,77010,342118,368Mar 05 05:40 PM
Obenshain AndrewPresident and CEOMar 04 '24Sale1.536,0959,311279,998Mar 05 05:40 PM
Klima Thomas JSee RemarksMar 04 '24Sale1.534,5736,986124,840Mar 05 05:39 PM
Klima Thomas JSee RemarksFeb 05 '24Sale0.902,7142,449129,413Feb 06 04:07 PM
Vittiglio JosephChief Business & Legal OfficerFeb 05 '24Sale0.905,2174,70844,783Feb 06 04:07 PM
Obenshain AndrewPresident and CEOFeb 05 '24Sale0.901,8791,696286,093Feb 06 04:07 PM
Obenshain AndrewPresident and CEOJan 05 '24Sale1.433,1624,520287,972Jan 09 04:05 PM
Colvin Richard AChief Medical OfficerJan 05 '24Sale1.42597845125,138Jan 09 04:05 PM
Krawtschuk ChristopherChief Financial OfficerDec 06 '23Sale4.524,52620,43745,474Dec 08 04:42 PM